Abstracts

Pediatrics 
Fragmento

1. EFFICACY OF TOCILIZUMAB IN REFRACTORY SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. R.Eraso1,2,3, MP Velásquez3 1Universidad de Antioquia (UdeA). 2 Hospital Pablo Tobón Uribe. 3 Hospital Universitario San Vicente Fundación, Medellín, Colombia. Introduction: Treatment with Tocilizumab (TCZ) - antiIL-6 has proven useful in systemic juvenile idiopathic arthritis refractory to DMARDs or antiTNF (RSJIA). The efficacy and safety of TCZ in four patients with RSJIA was determined . Materials and methods: We reviewed the medical records of patients on therapy with TCZ. We included six variables to determine the ACRPed response: number of active joints, number of joints with limited range of motion, global VAS assessment by the physician, global VAS assessment by the patient or parent, CHAQ and erithrosedimentation rate. We evaluated the change in steroid dose and CRP levels and adverse events were described. Results: Four patients were included: three boys and one girl. Average age: 10, 7 years. All were refractory to methotrexate and three were refractory to antiTNF, one was also refractory to Rituximab. One patient did not use antiTNF by a history of tuberculosis. Average dose of prednisolone pre-treatment: 0.8 mg/kg/day. Average level of CRP pre-treatment:10.8mg/dl. All patients received TCZ: 8mg/kg intravenous every fifteen days except in one patient that was applied monthly. Median follow-up after TCZ: 15 months (range: 4-21). Results in the last clinical control: ACRPed 70 response: Three patients , ACRPed50: one patient; average dose of prednisolone: 0.23mg/kg/dia, average level of CRP: 0.13mg/dl. Adverse reactions: infection: one patient (recurrent upper respiratory tract infection), angioedema: one patient, mild neutropenia; one patient. Conclusion: TCZ showed efficacy in the treatment of four patients with RSJIA with an acceptable safety profile.

Palabras clave:

2012-01-12   |   360 visitas   |   Evalua este artículo 0 valoraciones

Vol. 18 Núm.5. Agosto 2011 Pags. 92 Rev. Colomb. Reumatol. 2011; 18(Supl. 1)